Back

Age-targeted dose allocation can halve COVID-19 vaccine requirements

Meehan, M. T.; Cocks, D. G.; Caldwell, J. M.; Trauer, J. M.; Adekunle, A. I.; Ragonnet, R. R.; McBryde, E. S.

2020-10-11 infectious diseases
10.1101/2020.10.08.20208108 medRxiv
Show abstract

In anticipation of COVID-19 vaccine deployment, we use an age-structured mathematical model to investigate the benefits of optimizing age-specific dose allocation to suppress the transmission, morbidity and mortality of SARS-CoV-2 and the associated disease, COVID-19. To minimize transmission, we find that the highest priority individuals across 179 countries are typically those between 30 and 59 years of age because of their high contact rates and higher risk of infection and disease. Conversely, morbidity and mortality are initially most effectively reduced by targeting 60+ year olds who are more likely to experience severe disease. However, when population-level coverage is sufficient -- such that herd immunity can be achieved through targeted dose allocation -- prioritizing middle-aged individuals becomes the most effective strategy to minimize hospitalizations and deaths. For each metric considered, we show that optimizing the allocation of vaccine doses can more than double their effectiveness.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.